Gallacher Capital Management’s Sanofi SNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$272K Sell
6,375
-878
-12% -$39.2K 0.15% 208
2026
Q1
$349K Sell
7,253
-2,296
-24% -$107K 0.13% 205
2025
Q4
$463K Sell
9,549
-831
-8% -$41.2K 0.18% 162
2025
Q3
$490K Buy
10,380
+1,584
+18% +$76.4K 0.19% 174
2025
Q2
$425K Buy
8,796
+2,471
+39% +$126K 0.2% 153
2025
Q1
$351K Buy
6,325
+721
+13% +$39K 0.17% 172
2024
Q4
$270K Buy
5,604
+15
+0.3% +$763 0.13% 212
2024
Q3
$322K Sell
5,589
-821
-13% -$44.3K 0.15% 189
2024
Q2
$311K Sell
6,410
-276
-4% -$13.3K 0.16% 176
2024
Q1
$325K Buy
6,686
+843
+14% +$41.2K 0.16% 175
2023
Q4
$291K Buy
5,843
+128
+2% +$6.26K 0.16% 171
2023
Q3
$307K Buy
5,715
+245
+4% +$13.1K 0.19% 140
2023
Q2
$295K Buy
5,470
+421
+8% +$22.7K 0.17% 171
2023
Q1
$275K Buy
5,049
+801
+19% +$39K 0.16% 177
2022
Q4
$206K Buy
+4,248
New +$186K 0.12% 218

Other funds holding SNY

Gallacher Capital Management's SNY Position: Q2 2026 in Review

Gallacher Capital Management reduced its Sanofi (SNY) stake by 12% in Q2 2026, selling an estimated $39.2K and leaving 6,375 shares worth $272K. The position accounts for 0.15% of the portfolio, ranked #208.

Gallacher Capital Management first reported a position in SNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $490K in Q3 2025. 160 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

  • Gallacher Capital Management held 6,375 shares of Sanofi worth $272K as of Q2 2026.
  • Gallacher Capital Management sold 878 Sanofi shares in Q2 2026, an estimated $39.2K.
  • Sanofi made up 0.15% of Gallacher Capital Management's portfolio in Q2 2026, its #208 holding.
  • Gallacher Capital Management first reported a position in Sanofi in Q4 2022 and has held it in 15 quarters since.
  • Gallacher Capital Management's Sanofi position peaked at $490K in Q3 2025.
  • 160 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on Gallacher Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.